Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study.

ABSTRACT:

Background

Biologics are often required for the treatment of hidradenitis suppurativa (HS). However, data on the drug survival of biologics in daily practice are currently lacking.

Objectives

To assess the drug survival of antitumour necrosis factor biologics in a daily practice cohort of patients with HS and to identify predictors for drug survival.

Methods

A retrospective multicentre study was performed in two academic dermatology centres in the Netherlands. Adult patients with HS using biologics between 2008 and 2020 were included. Drug survival was analysed with Kaplan-Meier survival curves and predictors of survival with univariate Cox regression analysis.

Results

The overall drug survival of adalimumab (n = 104) at 12 and 24 months was 56·3% and 30·5%, re

SUBMITTER: Prens LM 

PROVIDER: S-EPMC8360014 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature